

HempStreet partners with UK-based MGC Pharma

04 May 2022 | News

Indian patients will now have access to CimetrA and CannEpil for COVID-19 and epileptic patients



HempStreet, India's first research to retail venture in the medicinal cannabis sector, has partnered with European bio-pharma and phytocannabinoid company MGC Pharma.

Headquartered in the UK, MGC Pharma has been working on polyherbal formulations based on cannabis and other phytopharmaceuticals. MGC Pharma has two proprietary formulations CimetrA and CannEpil. CimetrA is effective in arresting the cytokine storm, a symptom of COVID-19. It is made of natural-sourced ingredients including Artemisinin, Curcumin, and Boswellia serrata. CannEpil is a phytocannabinoid-based medicine that effectively treats drug-resistant Epilepsy. Both products have undergone successful Phase II clinical trials.

Through this partnership Indian patients will now have access to these medicines, starting with CimetrA, which had an immediate need as there are currently over 15 million individuals (approximately 30 per cent of all COVID-19 recoverees in India) said to be experiencing some form of post- or long- COVID- 19 related symptoms.

The partnership will also accelerate HempStreet's upcoming venture – transdermal delivery technology for cannabinoids – to launch in the markets beyond Asia with the help of MGC Pharma's widespread distribution network in Australia, the UK, Brazil and Ireland.